Biogen flips '26 guidance from expected decline to sales increase

With increased sales of its newer drugs compensating for declining revenues from its multiple sclerosis (MS) portfolio, Biogen is once again positioned for a “growth story,” CEO Chris Viehbacher sa | With increased sales of its newer drugs compensating for declining revenues from its multiple sclerosis portfolio, Biogen finally is positioned once again for a “growth story,” CEO Chris Viehbacher said Wednesday during the company’s second quarter earnings call. The company has flipped its 2026 revenue guidance from an expected mid-single digit decline in 2026 to a mid-single digit increase.